- 2013-04-28 20:38Delcath shares hammered on trial enrollment suspension
- 2013-04-28 20:37Genzyme lands $345M acquisition of Bioenvision
- 2013-04-28 20:36Targacept pushes depression therapy into the clinic
- 2013-04-28 20:36SPOTLIGHT: Enrollment wrapped on Provenge Phase III
- 2013-04-28 20:35ALSO NOTED: Bentley spins off drug delivery biz; Immunosyn names new CEO; and much more...
- 2013-04-28 20:34Avant, Celldex merge in $115M stock deal
- 2013-04-28 20:34FDA criticizes Aventis for Ketek study failures
- 2013-04-28 20:33In new approach, R&D units are spun off
- 2013-04-28 20:32Xencor adds $15M to fifth VC round
- 2013-04-28 20:31Sirion touts Phase III data for eye therapy
- 2013-04-28 20:31SPOTLIGHT: EU biosimilars market opens up
- 2013-04-28 20:30ALSO NOTED: GSK cuts 5,000 jobs; Codexis opens Singapore lab;Reliant sets IPO terms;and much more...
- 2013-04-28 20:29Threshold slashes staff in effort to cut burn rate
- 2013-04-28 20:29Pharmos cuts staff at Israeli subsidiary
- 2013-04-28 20:28SPOTLIGHT: Nycomed to acquire Bradley Pharma
- 2013-04-28 20:27ALSO NOTED: Lilly grabs rights to pain therapy; Study outlines billions in potential R&D savings; Ta
- 2013-04-28 20:26Safety questions cloud future of Takeda's TAK-475
- 2013-04-28 20:26Forget CAT: the name is MedImmune now
- 2013-04-28 20:25New malaria vaccine offers better protection
- 2013-04-28 20:25ChemGenex restructures, focuses on cancer drugs
